Anthurium: Wholly-owned subsidiary has obtained the registration certificate for Clindamycin hydrochloride palmitate particles.

Announcement of Euphorbia, the wholly-owned subsidiary Guangzhou Euphorbia Pharmaceutical Co., Ltd. has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Clindamycin Hydrochloride Palmitate Granules. The indications for Clindamycin Hydrochloride Palmitate Granules are as follows: Clindamycin is suitable for severe infections caused by sensitive anaerobic bacteria. Clindamycin is suitable for severe infections caused by sensitive strains of streptococcus, pneumococcus, and staphylococcus, but only for patients allergic to penicillin or patients for whom the use of penicillin is deemed unsuitable by a doctor. The package insert contains clear instructions for pediatric use and dosage.